Boehringer Ingelheim Animal Health: 2015 European PRRS Research Award open for submissions until July 31st

Ingelheim, Germany, 1 July 2015 - For the second time, Boehringer Ingelheim Animal Health sponsors the European PRRS Research Award to support applied research for the improved control of the swine disease PRRS (Porcine Reproductive and Respiratory Syndrome). As the company announced in March, the submissions for the 2015 European PRRS Research Award are open until July 31st. To continuously work on practical approaches to manage the disease, Boehringer Ingelheim Animal Health will provide three grants of 25,000 euros each to fund research proposals that will generate new and practical information to better understand this devastating and costly disease.

The objectives of this initiative are to encourage research resulting in practical application strategies to control PRRS and to enhance the interaction among swine researchers and veterinarians. In addition, Boehringer Ingelheim Animal Health’s intention is to enhance communication in the industry on practical PRRS control strategies and to reward research excellence. The PRRS virus infects pigs around the globe causing respiratory tract illness in growing pigs and reproductive failure in breeding stock.  Boehringer Ingelheim Animal Health strives to find solutions for an improved PRRS control.

Applications to submit research proposals can be made on www.prrs.com. Each proposal will be reviewed by an independent review board of highly recognized swine industry professionals including researchers and practitioners. The board will select proposals based on several factors, including their significance, potential for impact to the swine industry, originality and innovation.

The winners of this year’s European PRRS Research Award will be announced in October 2015.

For more information please visit www.prrs.com

Boehringer Ingelheim
The Boehringer Ingelheim group is one of the world’s 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, Boehringer Ingelheim operates globally with 146 affiliates and a total of more than 47,700 employees. The focus of the family-owned company, founded in 1885, is researching, developing, manufacturing and marketing new medications of high therapeutic value for human and veterinary medicine.

Social responsibility is an important element of the corporate culture at Boehringer Ingelheim. This includes worldwide involvement in social projects, such as the initiative “Making more Health” and caring for the employees. Respect, equal opportunities and reconciling career and family form the foundation of the mutual cooperation. In everything it does, the company focuses on environmental protection and sustainability.

In 2014, Boehringer Ingelheim achieved net sales of about 13.3 billion euros. R&D expenditure corresponds to 19.9 per cent of its net sales.

For more information please visit www.boehringer-ingelheim.com